 | Up a level |
2020
Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M. and Oettle, H. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur. J. Cancer, 138. S. 172 - 182. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2016
Baretton, G., Dietel, M., Gaiser, T., Kirchner, T., Kreipe, H. H., Quaas, A., Roecken, C., Rueschoff, J., Tannapfel, A., Lordick, F., Al-Batran, S., Hofheinz, R., Lorenzen, S., Moehler, M. and Thuss-Patience, P. (2016). HER2 testing in gastric cancer. Results of ameeting of German experts. Pathologe, 37 (4). S. 361 - 367. NEW YORK: SPRINGER. ISSN 1432-1963
2013
Hoehler, T., von Wichert, G., Schimanski, C., Kanzler, S., Moehler, M. H., Hinke, A., Seufferlein, T., Siebler, J., Hochhaus, A., Arnold, D., Hallek, M., Hofheinz, R. and Hacker, U. T. (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br. J. Cancer, 109 (6). S. 1408 - 1414. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827